Metis Global Partners LLC Has $26.94 Million Stock Holdings in Eli Lilly and Company (NYSE:LLY)

Metis Global Partners LLC raised its holdings in Eli Lilly and Company (NYSE:LLY) by 13.0% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 46,217 shares of the company’s stock after buying an additional 5,332 shares during the quarter. Eli Lilly and Company accounts for about 1.1% of Metis Global Partners LLC’s investment portfolio, making the stock its 16th largest position. Metis Global Partners LLC’s holdings in Eli Lilly and Company were worth $26,941,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in LLY. Vanguard Group Inc. grew its position in Eli Lilly and Company by 0.9% during the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock worth $37,908,273,000 after buying an additional 659,838 shares in the last quarter. Morgan Stanley grew its holdings in shares of Eli Lilly and Company by 0.7% during the 3rd quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock worth $6,738,605,000 after purchasing an additional 83,915 shares in the last quarter. Northern Trust Corp increased its position in shares of Eli Lilly and Company by 3.6% during the third quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock valued at $5,456,314,000 after purchasing an additional 355,317 shares during the period. International Assets Investment Management LLC raised its stake in shares of Eli Lilly and Company by 61,268.8% in the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after purchasing an additional 7,330,815 shares in the last quarter. Finally, Fisher Asset Management LLC lifted its position in Eli Lilly and Company by 2.0% in the fourth quarter. Fisher Asset Management LLC now owns 4,544,585 shares of the company’s stock worth $2,649,130,000 after purchasing an additional 87,511 shares during the period. 82.53% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. DZ Bank lowered shares of Eli Lilly and Company from a “buy” rating to a “hold” rating and set a $820.00 price target on the stock. in a report on Wednesday, February 21st. Bank of America increased their price target on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the stock a “buy” rating in a research report on Friday, March 1st. Truist Financial boosted their target price on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research note on Wednesday. TheStreet raised shares of Eli Lilly and Company from a “c+” rating to a “b” rating in a research note on Friday, March 8th. Finally, Morgan Stanley lifted their target price on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the company an “overweight” rating in a research note on Friday, February 16th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $757.95.

Eli Lilly and Company Trading Down 2.8 %

Shares of LLY traded down $20.94 on Friday, reaching $734.97. 4,595,138 shares of the company’s stock were exchanged, compared to its average volume of 2,629,045. The business has a 50 day moving average price of $761.06 and a two-hundred day moving average price of $672.28. Eli Lilly and Company has a 12 month low of $419.80 and a 12 month high of $800.78. The stock has a market capitalization of $698.52 billion, a P/E ratio of 108.24, a price-to-earnings-growth ratio of 1.46 and a beta of 0.37. The company has a current ratio of 1.35, a quick ratio of 0.73 and a debt-to-equity ratio of 1.90.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Tuesday, April 30th. The company reported $2.58 EPS for the quarter, beating the consensus estimate of $2.53 by $0.05. The company had revenue of $8.77 billion during the quarter, compared to analysts’ expectations of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 56.98%. The business’s revenue for the quarter was up 26.0% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.62 EPS. Research analysts anticipate that Eli Lilly and Company will post 13.82 earnings per share for the current year.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.